Prostate cancer stem cells: a new target for therapy

Area of Science:

• Oncology
• Cancer Stem Cell Biology

Background:

• Prostate cancer is the most common cancer in US males, with treatment challenges linked to tumor heterogeneity.
• Prostate cancer stem cells (PCSCs) are hypothesized to explain treatment resistance and disease recurrence.
• Identifying and isolating PCSCs is crucial for understanding prostate cancer etiology and developing effective therapies.

Purpose of the Study:

• To identify and characterize prostate cancer stem cells.
• To investigate the potential of PCSCs as therapeutic targets for hormone-refractory prostate cancer.
• To explore the relationship between PCSC gene expression and clinical outcomes.

Main Methods:

• Selection of cells with a CD133(+)/alpha 2 beta 1 integrin/CD44(+) phenotype from human prostate cancers.
• Analysis of PCSC gene expression signatures.
• Correlation of PCSC characteristics with Gleason grade and patient prognosis.

Main Results:

• A CD133(+)/alpha 2 beta 1 integrin/CD44(+) cell population was enriched for tumor-initiating capacity in human prostate cancers.
• PCSCs lack androgen receptors, conferring resistance to androgen-based therapies.
• PCSC gene expression profiles correlate with Gleason grade and patient outcomes.
• PCSCs exhibit a quiescent nature, posing challenges for efficacy assays.

Conclusions:

• Prostate cancer stem cells are a distinct population with tumor-initiating properties and resistance to current therapies.
• Targeting PCSCs presents a promising strategy for developing more durable and effective treatments for prostate cancer, particularly hormone-refractory disease.
• While scarce, PCSCs offer novel therapeutic avenues beyond conventional treatments targeting the bulk tumor mass.